EDIT-401 CRISPR therapy targets LDL reduction; Phase I set for Australia
EDIT-401 in vivo CRISPR aims to reduce LDL cholesterol by upregulating LDLR in the liver. Phase I trials will start in Australia; safety data is expected in Q1 2027, with U.S. entry planned for 2027.